Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - lamivudine; zidovudine - tablet, film coated - 150 mg - lamivudine 150 mg; zidovudine 300 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - emtricitabine; tenofovir disoproxil - film-coated tablet - 200/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - tenofovir disoproxil; emtricitabine - film-coated tablet - 200mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; tenofovir disoproxil and emtricitabine

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - abacavir; lamivudine - film-coated tablet - 600/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

European Union - English - EMA (European Medicines Agency)

zentiva k.s. - efavirenz, emtricitabine, tenofovir disoproxil, phosphate - hiv infections - antivirals for systemic use, - efavirenz/emtricitabine/tenofovir disoproxil zentiva is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. it is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults aged 18 years and over with virologic suppression to hiv-1 rna levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in efavirenz/emtricitabine/tenofovir disoproxil zentiva prior to initiation of their first antiretroviral treatment regimen., the demonstration of the benefit of the combination efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavir

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.